Mechanism of Action

VELTASSA binds K⁺ throughout the GI tract and acts longest in the colon, where K⁺ is most abundant^1–4

When K⁺ excretion is disrupted by CKD and/or RAAS inhibition, K⁺ may build up in the colon.

VELTASSA is fully ionized at the physiological pH of the colon where it exchanges potassium for calcium

Na⁺ exchange is greatest in the ascending colon
Normal concentration of K⁺ is 7x higher in the colon than in the small intestine, and K⁺ secretion in the colon is further upregulated in patients with CKD
VELTASSA exchanges Ca⁺⁺ for K⁺ where K⁺ is most abundant
- VELTASSA is designed to be fully ionized at the physiological pH of the colon for optimal ion exchange
- VELTASSA is designed to exchange Ca⁺⁺ for K⁺ in the colon, where Ca⁺⁺ is minimally absorbed
After VELTASSA binds to K⁺, the patiromer beads are excreted through feces, leading to the removal of excess K⁺ from the body

Get important updates and information about VELTASSA

VELTASSA is different from other K⁺ binders

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

INDICATION & Important Safety Information

Important Safety Information

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

WARNINGS AND PRECAUTIONS

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnecemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnecemia. In clinical studies, hypomagnecemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnecemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnecemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.

VELTASSA binds K+ throughout the GI tract and acts longest in the colon, where K+ is most abundant1–4

INDICATION

INDICATION & Important Safety Information

Important Safety Information

INDICATION

IMPORTANT SAFETY INFORMATION

VELTASSA binds K⁺ throughout the GI tract and acts longest in the colon, where K⁺ is most abundant^1–4